NewAmsterdam Historical Balance Sheet

NAMSW Stock

9.69 0.16 1.68%

Trend analysis of NewAmsterdam Pharma balance sheet accounts such as Total Current Liabilities of 29.7 M provides information on NewAmsterdam Pharma's total assets, liabilities, and equity, which is the actual value of NewAmsterdam Pharma to its prevalent stockholders. By breaking down trends over time using NewAmsterdam Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining NewAmsterdam Pharma latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether NewAmsterdam Pharma is a good buy for the upcoming year.

NewAmsterdam Pharma Inventory

(1.62 Million)

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

About NewAmsterdam Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of NewAmsterdam Pharma at a specified time, usually calculated after every quarter, six months, or one year. NewAmsterdam Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of NewAmsterdam Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which NewAmsterdam currently owns. An asset can also be divided into two categories, current and non-current.

NewAmsterdam Pharma Balance Sheet Chart

At this time, NewAmsterdam Pharma's Other Current Liabilities is fairly stable compared to the past year. Property Plant And Equipment Net is likely to climb to about 122.9 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 57 K in 2024.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Total Assets

Total assets refers to the total amount of NewAmsterdam Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in NewAmsterdam Pharma books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on NewAmsterdam Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of NewAmsterdam Pharma are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from NewAmsterdam Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into NewAmsterdam Pharma current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.At this time, NewAmsterdam Pharma's Other Current Liabilities is fairly stable compared to the past year. Property Plant And Equipment Net is likely to climb to about 122.9 K in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 57 K in 2024.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	164K	118K	60K	57K
Total Assets	59.8M	531.6M	347.1M	260.6M

Short Long Term Debt Total Total Assets

NewAmsterdam Pharma balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Current Deferred Revenue
Total Assets		-0.83	0.75	0.89	1.0	0.7	-0.98	-0.75	0.89	1.0	0.77	0.83	1.0	0.56	0.07	0.8	0.93	1.0	0.78	-0.48	1.0	0.77	1.0	-0.83	0.77	0.99
Short Long Term Debt Total	-0.83		-0.78	-0.74	-0.83	-0.96	0.87	0.8	-0.93	-0.84	-0.45	-1.0	-0.84	-0.66	0.48	-0.94	-0.77	-0.82	-0.94	0.62	-0.84	-0.51	-0.85	1.0	-0.51	-0.8
Other Current Liab	0.75	-0.78		0.89	0.73	0.57	-0.85	-1.0	0.87	0.79	0.17	0.78	0.79	0.97	-0.05	0.57	0.87	0.73	0.55	-0.91	0.79	0.17	0.77	-0.78	0.17	0.78
Total Current Liabilities	0.89	-0.74	0.89		0.87	0.53	-0.91	-0.9	0.92	0.92	0.43	0.74	0.92	0.78	0.12	0.56	1.0	0.87	0.55	-0.63	0.92	0.42	0.9	-0.74	0.42	0.86
Total Stockholder Equity	1.0	-0.83	0.73	0.87		0.71	-0.98	-0.74	0.88	0.99	0.79	0.83	0.99	0.53	0.07	0.81	0.91	1.0	0.79	-0.46	0.99	0.79	1.0	-0.83	0.79	0.99
Property Plant And Equipment Net	0.7	-0.96	0.57	0.53	0.71		-0.73	-0.6	0.81	0.7	0.45	0.96	0.7	0.45	-0.65	0.98	0.57	0.7	0.98	-0.44	0.71	0.54	0.72	-0.96	0.54	0.66
Net Debt	-0.98	0.87	-0.85	-0.91	-0.98	-0.73		0.85	-0.93	-0.99	-0.66	-0.87	-0.99	-0.69	-0.02	-0.8	-0.94	-0.98	-0.79	0.63	-0.99	-0.66	-0.99	0.87	-0.66	-0.99
Retained Earnings	-0.75	0.8	-1.0	-0.9	-0.74	-0.6	0.85		-0.9	-0.8	-0.17	-0.8	-0.8	-0.96	0.09	-0.59	-0.88	-0.73	-0.58	0.9	-0.8	-0.17	-0.78	0.8	-0.17	-0.77
Accounts Payable	0.89	-0.93	0.87	0.92	0.88	0.81	-0.93	-0.9		0.92	0.44	0.93	0.92	0.76	-0.24	0.8	0.93	0.87	0.8	-0.63	0.92	0.47	0.92	-0.93	0.47	0.85
Cash	1.0	-0.84	0.79	0.92	0.99	0.7	-0.99	-0.8	0.92		0.71	0.84	1.0	0.61	0.06	0.78	0.95	0.99	0.77	-0.52	1.0	0.72	1.0	-0.84	0.72	0.98
Non Current Assets Total	0.77	-0.45	0.17	0.43	0.79	0.45	-0.66	-0.17	0.44	0.71		0.45	0.71	-0.09	0.24	0.62	0.51	0.79	0.61	0.1	0.72	0.99	0.73	-0.45	0.99	0.75
Non Currrent Assets Other	0.83	-1.0	0.78	0.74	0.83	0.96	-0.87	-0.8	0.93	0.84	0.45		0.84	0.66	-0.48	0.95	0.76	0.82	0.94	-0.61	0.84	0.52	0.85	-1.0	0.52	0.79
Cash And Short Term Investments	1.0	-0.84	0.79	0.92	0.99	0.7	-0.99	-0.8	0.92	1.0	0.71	0.84		0.61	0.06	0.78	0.95	0.99	0.77	-0.52	1.0	0.72	1.0	-0.84	0.72	0.98
Common Stock Shares Outstanding	0.56	-0.66	0.97	0.78	0.53	0.45	-0.69	-0.96	0.76	0.61	-0.09	0.66	0.61		-0.1	0.4	0.75	0.53	0.39	-0.95	0.61	-0.09	0.59	-0.66	-0.09	0.59
Non Current Liabilities Total	0.07	0.48	-0.05	0.12	0.07	-0.65	-0.02	0.09	-0.24	0.06	0.24	-0.48	0.06	-0.1		-0.49	0.13	0.09	-0.51	0.1	0.05	0.12	0.04	0.48	0.12	0.14
Other Current Assets	0.8	-0.94	0.57	0.56	0.81	0.98	-0.8	-0.59	0.8	0.78	0.62	0.95	0.78	0.4	-0.49		0.62	0.8	1.0	-0.41	0.79	0.69	0.8	-0.95	0.69	0.77
Total Liab	0.93	-0.77	0.87	1.0	0.91	0.57	-0.94	-0.88	0.93	0.95	0.51	0.76	0.95	0.75	0.13	0.62		0.91	0.6	-0.61	0.95	0.5	0.94	-0.76	0.5	0.91
Net Invested Capital	1.0	-0.82	0.73	0.87	1.0	0.7	-0.98	-0.73	0.87	0.99	0.79	0.82	0.99	0.53	0.09	0.8	0.91		0.78	-0.46	0.99	0.79	1.0	-0.81	0.79	0.99
Property Plant And Equipment Gross	0.78	-0.94	0.55	0.55	0.79	0.98	-0.79	-0.58	0.8	0.77	0.61	0.94	0.77	0.39	-0.51	1.0	0.6	0.78		-0.4	0.77	0.69	0.79	-0.94	0.69	0.75
Short Long Term Debt	-0.48	0.62	-0.91	-0.63	-0.46	-0.44	0.63	0.9	-0.63	-0.52	0.1	-0.61	-0.52	-0.95	0.1	-0.41	-0.61	-0.46	-0.4		-0.52	0.1	-0.51	0.61	0.1	-0.55
Total Current Assets	1.0	-0.84	0.79	0.92	0.99	0.71	-0.99	-0.8	0.92	1.0	0.72	0.84	1.0	0.61	0.05	0.79	0.95	0.99	0.77	-0.52		0.72	1.0	-0.84	0.72	0.98
Capital Stock	0.77	-0.51	0.17	0.42	0.79	0.54	-0.66	-0.17	0.47	0.72	0.99	0.52	0.72	-0.09	0.12	0.69	0.5	0.79	0.69	0.1	0.72		0.74	-0.52	1.0	0.75
Net Working Capital	1.0	-0.85	0.77	0.9	1.0	0.72	-0.99	-0.78	0.92	1.0	0.73	0.85	1.0	0.59	0.04	0.8	0.94	1.0	0.79	-0.51	1.0	0.74		-0.84	0.74	0.98
Short Term Debt	-0.83	1.0	-0.78	-0.74	-0.83	-0.96	0.87	0.8	-0.93	-0.84	-0.45	-1.0	-0.84	-0.66	0.48	-0.95	-0.76	-0.81	-0.94	0.61	-0.84	-0.52	-0.84		-0.52	-0.79
Common Stock	0.77	-0.51	0.17	0.42	0.79	0.54	-0.66	-0.17	0.47	0.72	0.99	0.52	0.72	-0.09	0.12	0.69	0.5	0.79	0.69	0.1	0.72	1.0	0.74	-0.52		0.75
Current Deferred Revenue	0.99	-0.8	0.78	0.86	0.99	0.66	-0.99	-0.77	0.85	0.98	0.75	0.79	0.98	0.59	0.14	0.77	0.91	0.99	0.75	-0.55	0.98	0.75	0.98	-0.79	0.75

Click cells to compare fundamentals

NewAmsterdam Pharma Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

NewAmsterdam Historical Balance Sheet

NewAmsterdam Pharma Inventory

(1.62 Million)

About NewAmsterdam Balance Sheet Analysis

NewAmsterdam Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

NewAmsterdam Pharma balance sheet Correlations

NewAmsterdam Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for NewAmsterdam Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Net Invested Capital	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Working Capital	+ 1.0	Total Assets

Short Term Debt	- 1.0	Non Currrent Assets Other
Retained Earnings	- 1.0	Other Current Liab
Non Currrent Assets Other	- 1.0	Short Long Term Debt Total
Current Deferred Revenue	- 0.99	Net Debt
Net Working Capital	- 0.99	Net Debt
Total Current Assets	- 0.99	Net Debt